elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Gemcitabine
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Gemcitabine
RIS
0.002
(Research Intensity Score)
Papers
212
Top papers
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · 972 citations
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · 1074 citations
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2023 · 479 citations
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022 · 1141 citations
Pancreatic Cancer
2021 · 1892 citations
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
2023 · 448 citations
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
2024 · 274 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2023 · 270 citations
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 · 142 citations
Newest papers
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · 12 citations
lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis: Am J Cancer Res. 2023; 13(6): 2732-2750
2026 · 5 citations
A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
2026 · 3 citations
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
2026 · 2 citations
Exceptional long-term survival in a patient with recurrent pancreatic carcinoma on adjuvant tegafur–gimeracil–oteracil potassium: a case report
2026 · 2 citations
A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy
2026 · 1 citations
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
2026
A survey method using three indicators (total, regimen, and each line contribution periods) to understand the actual treatment status for patients with recurrent ovarian cancer in real-world clinical practice
2026
Ferroptosis Suppression by the M 6 A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
2026
Browse all papers →
Gemcitabine's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Gemcitabine's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link